CDSCO Approves India's First Dengue Vaccine, Strengthening National Dengue Prevention Efforts

Why in news

The Central Drugs Standard Control Organisation (CDSCO) has approved Qdenga®, India's first dengue vaccine, for individuals aged 4-60 years, marking a significant step in the nation's dengue prevention strategy.

Exam relevance

GS2, GS3 · Governance, Science & Technology, Society · Prelims · Mains

Key facts

1. CDSCO has granted marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga®.
2. This is the first dengue vaccine approved in India.
3. The vaccine is for the prevention of dengue disease in individuals aged 4–60 years.
4. Qdenga® is manufactured by Takeda GmbH, Germany, and will be imported by M/s Takeda Biopharmaceuticals India Pvt. Ltd.
5. The vaccine has been approved in 42 countries and has WHO Prequalification.
6. It is a live, attenuated tetravalent dengue vaccine developed using recombinant DNA technology.
7. The vaccine is produced in Vero cells with engineered dengue virus type-2 backbone and contains genetically modified organisms (GMOs).
8. It is administered as a subcutaneous injection after reconstitution of a freeze-dried powder.

Prelims pointers

• CDSCO is the central drug regulatory authority in India.
• Qdenga® is the first dengue vaccine approved in India.
• The vaccine is approved for individuals aged 4–60 years.
• Qdenga® is a live, attenuated tetravalent dengue vaccine.
• It utilizes recombinant DNA technology and contains GMOs.
• The vaccine has WHO Prequalification and is approved in 42 countries.

Mains practice question

Discuss the significance of the approval of India's first dengue vaccine by CDSCO. What are the potential implications for public health and the challenges associated with its widespread implementation?

Static linkage

The approval of Qdenga® by CDSCO falls under the purview of drug regulation in India, governed by the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945. CDSCO acts as the central regulatory authority for ensuring the quality, safety, and efficacy of drugs and medical devices in the country. This development is also linked to public health initiatives aimed at controlling vector-borne diseases like dengue, which is a significant health challenge in India.

Significance

The approval of India's first dengue vaccine is a crucial development for public health, offering a new tool to combat the significant burden of dengue disease. It signifies a step forward in the country's preparedness and response mechanisms for vector-borne diseases. The vaccine's availability could potentially reduce dengue incidence, severity, and associated healthcare costs, thereby improving the overall health outcomes of the population. Furthermore, it highlights India's capacity to evaluate and approve advanced biotechnological products, aligning with global health standards.